Scientists interested in anti-aging research are being pointed to new treatments that build collagen or other proteins absorbed in the extracellular matrix that supports body tissue and bone. And a team of researchers is suggesting that cosmetics companies--relentlessly focused on prolonging youthful looks--may be the best sponsors of R&D programs focused on these new pharmaceuticals.
Howard Hughes Medical Institute investigator Joseph DeRisi is working on a new malaria treatment that makes infected red blood cells an inviting target for the human immune system. And the team behind the effort is ramping up a human safety study in healthy volunteers as the first step in the clinical journey to prove its effectiveness.
In an era of cutbacks in basic research by Big Pharma, companies are increasingly relying on academic and nonprofit collaborations for basic science and drug discovery research as output and productivity in the industry are declining.
Meanwhile, for academic researchers, these alliances are becoming just as crucial at a time when funding from the U.S. National Institutes of Health--the world's biggest backer of biomedical research--remains tight. It's a symbiotic relationship that we'll likely continue to see for the foreseeable future as Big Pharma's pipeline dries up and federal R&D spending remains static.
The year isn't over yet, but already some big players have formed some notable unions in 2014.
POPULAR COMMENT THREADS
Researchers have hit on a new approach to creating functional melanocytes, the body's pigment-producing cells. And their work could spur a fresh approach to screening and developing new drugs for melanoma as well as producing new cell-based therapies for a variety of skin diseases.
The buildup of fat in liver cells--which leads to nonalcoholic fatty liver disease--has become a major public health issue. Now investigators say they have their eyes on a potential pathway for new drug development.
After 14 years of work and $1.2 billion in costs with nothing to show for it, the NIH has decided to cut its blockbuster losses on an ambitious but bungled attempt to study environmental influences on children's health.
A team of neurologists at UT Southwestern notes that EGFR is activated when epidermal growth factor (EGF) binds to it, promoting tumor growth and damping down its response to chemo. And they believe they may have found a particular pathway during their research that could prove attractive for developers involved in oncology.
A research team says it has developed a new type of stem cell--capable of developing into any kind of tissue--that could pave the way to new cell lines that could be made more efficiently, opening up its potential in R&D.
In order to survive, cancer cells often rely on the protein kinase C epsilon signaling pathway to sort out tangled DNA that would otherwise trigger their destruction, according to a team at Cancer Research UK. So blocking the pathway could mark another line of attack against those cancers that depend on that "lifeline" the most.
From Our Sister Sites
The new president at Takeda has raided Sanofi for its new head of global R&D. And they're putting their new top scientist in Cambridge, MA, which is becoming the world headquarters of drug research for much of the pharma industry.
We now have a new record price for cancer treatment. Amgen's leukemia drug Blincyto, approved by the FDA this month to treat an uncommon form of the disease, will cost $178,000 per patient....